Non-metastatic cholestatic paraneoplastic syndrome associated with soft tissue sarcoma
- 作者Amanjit BAL; Usha DUTTA; Ashim DAS; Rakesh KOCCHAR; Kartar SINGH
- 卷第5卷
- 期第2期
- 印刷ISSN1743-7555
- 电子ISSN1743-7563
- 文件大小343.84KB
- 发表时间2009
- DOI10.1111/j.1743-7563.2009.01197.x
- 页码137-141
The use of real-world data in cancer drug developmentSkovlund, E.; Leufkens, H.G.M.; Smyth, J.F. · European Journal of Cancer · 2018
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real WorldMailankody, Sham; Prasad, Vinay · JAMA Oncology · 2016
A Foot In The Door Or One Foot In The Grave? The Role Of Real World Evidence In Cancer Drugs Fund Re-AppraisalsWalsh, S; Roibu, C; Macaulay, R · Value in Health · 2018
Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancerLi, Nanxin; Du, Ella X.; Chu, Lihao; Peeples, Miranda; Xie, Jipan; Barghout, Victoria; Tang, Derek H. · Expert Opinion on Pharmacotherapy · 2017
Real-World Analysis of the Efficacy of Rebiopsy and <i>EGFR</i> Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung CancerHong, Min Hee; Kim, Hye Ryun; Ahn, Beung-Chul; Heo, Su Jin; Kim, Jee Hung; Cho, Byoung Chul · Yonsei Medical Journal · 2019
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R.; Franceschetti, A. · Value in Health · 2018
PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung CancerSheffield, K.M.; Zhu, Y.E.; Fang, Y.; Winfree, K.B.; Cuyun Carter, G.; Huang, Y. · Journal of Thoracic Oncology · 2017